Vaccine impact on antimicrobial resistance to inform Gavi, the Vaccine Alliance’s 2018 Vaccine Investment Strategy: report from an expert survey
25 September 2019
While the rise of antimicrobial resistance (AMR) has been recognised as a major public health problem, the value of vaccines to control AMR is poorly defined. This expert survey was launched with the aim of informing the 2018 Vaccine Investment Strategy through which Gavi, the Vaccine Alliance prioritises future vaccine funding. This exercise focused on both vaccines currently supported by Gavi and under consideration for future funding.
Source: F1000Research
Authors: Maya Malarski, Mateusz Hasso-Agopsowicz, Adam Soble, Wilson Mok, Sophie Mathewson, Johan Vekemans
Effective Surveillance Healthy Patients
Display your AMR technology / product:
Global AMR Technologies Database
- Preventive – Diagnostic – Antimicrobial technologies
- Academia – Research Institutes – Start ups – SMEs – Multinationals
- Early research <-> near market (max 5)
- Global reach for funding / co-development / licensing
- No costs (until year end 2019)
Festive Launch Database 19 Nov Symposium Dinner ‘Emerging Antimicrobials and Diagnostics in AMR 2019‘
Click to join the Symposium Dinner (to join the Symposium separate registration obligatory)